INCA-BAR

CompletedPhase NA

Incretin Hormone Antagonism After Bariatric Surgery

Importance of Endogenous Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide for Postprandial Glucose Metabolism After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Surgery

Lead sponsor

Hvidovre University Hospital

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Bariatric Surgery, Healthy volunteers

Eligibility highlights

Primary endpoint

•Postprandial glucose

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03950245

Org study IDMH-INKA-BAR-19

Timeline

Milestones

Study first posted2019-05-15actual

Study start2019-07-01actual

Primary completion2021-04-16actual

Study completion2021-04-16actual

Last update posted2022-02-01actual

Assets

Investigational agents

Exenatide

Who this study enrolls

Bariatric SurgeryHealthy volunteers

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

, surgery groups:

•Age > 18 years

•RYGB or SG operation > 12 months prior to inclusion

•Weight stable (± 3 kg during the last month)

•HbA1c < 48 mmol/mol before surgery, and no history of diabetes

•HbA1c < 48 mmol/mol and fasting plasma glucose < 6.1 mmol/l at inclusion

Inclusion Criteria, control group:

•Age > 18 years

•no former RYGB- or SG operation

•Weight stable (± 3 kg during the last month)

•HbA1c < 48 mmol/mol, fasting plasma glucose < 6.1 mmol/l and no history of diabetes

Exclusion criteria

•Thyrotoxicosis or inadequately treated hypothyreosis

•Hemoglobin < 6.5 mmol/l at inclusion

•Pregnancy or breast feeding

•Medication affecting the planned examinations

Matching between groups

•Age

•Sex

•BMI at inclusion and for surgery groups also pre-surgery BMI

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

iAUC glucose

Time frame:240 minutes

Postprandial glucose

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Beta-cell glucose sensitivity (β-GS)

Time frame:240 minutes

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.